NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.180
+0.010 (0.85%)
At close: Sep 17, 2025, 4:00 PM EDT
1.180
0.00 (0.00%)
After-hours: Sep 17, 2025, 7:33 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$509,294
Market Cap
29.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NRSN News
- 7 days ago - NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons - PRNewsWire
- 13 days ago - NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price - PRNewsWire
- 6 weeks ago - NeuroSense Provides Business Update and Progress for the First Half of 2025 - PRNewsWire
- 2 months ago - Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community - PRNewsWire
- 4 months ago - Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - Benzinga
- 4 months ago - NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - PRNewsWire
- 5 months ago - NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - PRNewsWire
- 5 months ago - NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PRNewsWire